Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

mAbs

Volumn 4, Issue 3, 2012, Pages 326-340

  Chung, Shan ^a   Quarmby, Valerie ^a   Gao, Xiaoying ^a   Ying, Yong ^a   Lin, Linda ^a   Reed, Chae ^a   Fong, Chris ^a   Lau, Wendy ^a   Qiu, Zhihua J ^a   Shen, Amy ^a   Vanderlaan, Martin ^a   Song, An ^a  

^a GENENTECH INC   (United States)

Author keywords

Afucosylated antibody; Antibody dependent cellular cytotoxicity; Fc RIIIA; Fucosylation; Glycoform variants; Glycosylation; Monoclonal antibody

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; FUCOSE; GLYCAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; EFFECTOR CELL; EVALUATION; GENOTYPE; HUMAN; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; FUCOSE; HUMANS; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, IGG;

EID: 84860911340     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.19941     Document Type: Article

References (49)

1. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30:356-62; PMID:19552968; http://dx.doi.org/10.1016/j.tips.2009.04.007.
2. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007.
3. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx.doi.org/10.1038/nrd3365.
4. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/35018508.
5. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276:16469-77; PMID:11297532; http://dx.doi.org/10.1074/jbc.M100350200.
6. Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol 2001; 309:737-49; PMID:11397093; http://dx.doi.org/10.1006/jmbi.2001.4670.
7. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett 2002; 82:57-65; PMID:12008035; http://dx.doi.org/ 10.1016/S0165-2478(02)00019-6.
8. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0.
9. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10:477-86; PMID:10764836; http://dx.doi.org/10.1093/glycob/10.5.477.
10. Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, et al. Role of oligosaccharide residues of IgG1-Fc in Fcgamma RIIb binding. J Biol Chem 2001; 276:45539-47; PMID:11567028; http://dx.doi.org/10.1074/jbc.M107478200.
11. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA 1983; 80:6632-6; PMID:6579549; http://dx.doi.org/10.1073/pnas.80.21.6632.
12. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143:2595-601; PMID:2507634.
13. Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fcgamma RI and/or Fcgamma RII receptors. Biochem J 1989; 259:347-53; PMID:2524188.
14. Leatherbarrow RJ, Rademacher TW, Dwek RA, Woof JM, Clark A, Burton DR, et al. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol 1985; 22:407-15; PMID:4033665; http://dx.doi.org/10.1016/ 0161-5890(85)90125-7.
15. Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1,4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 2006; 93:851-61; PMID:16435400; http://dx.doi.org/10.1002/bit.20777.
16. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jefferis R. Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors. FASEB J 1995; 9:115-9; PMID:7821750.
17. Radaev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 2001; 276:16478-83; PMID:11297533; http://dx.doi.org/10.1074/jbc.M100351200.
18. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36:1370-80; PMID:9063885; http://dx.doi.org/10.1021/bi9621472.
19. Saba JA, Kunkel JP, Jan DC, Ens WE, Standing KG, Butler M, et al. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 2002; 305:16-31; PMID:12018942; http://dx.doi.org/10.1006/abio. 2002.5651.
20. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316:452-7; PMID:3927174; http://dx.doi.org/10.1038/316452a0.
21. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985; 54:631-64; PMID:3896128; http://dx.doi.org/10.1146/ annurev.bi.54.070185.003215.
22. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200.
23. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04- 0850.
24. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327-36; PMID:15788684; http://dx.doi.org/10.1158/1078-0432.CCR-04-2263.
25. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306:151-60; PMID:16219319; http://dx.doi.org/10.1016/j.jim.2005.08.009.
26. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 2004; 88:901-8; PMID:15515168; http://dx.doi.org/10.1002/bit.20326.
27. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614-22; PMID:15352059; http://dx.doi.org/10.1002/bit.20151.
28. Scallon B, McCarthy S, Radewonuk J, Cai A, Naso M, Raju TS, et al. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Int Immunopharmacol 2007; 7:761-72; PMID:17466910; http://dx.doi.org/10.1016/j. intimp.2007.01.014.
29. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009; 183:4782-91; PMID:19748990; http://dx.doi.org/10.4049/jimmunol.0900699.
30. Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, et al. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 2006; 140:777-83; PMID:17038352; http://dx.doi.org/10.1093/jb/mvj207.
31. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006; 12:2879-87; PMID:16675584; http://dx.doi.org/10.1158/1078-0432.CCR-05-2619.
32. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-geneencoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 2005; 306:93-103; PMID:16236307; http://dx.doi.org/10.1016/j. jim.2005.07.025.
33. Griggs J, Zinkewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009; 101:1807-12; PMID:19809433; http://dx.doi.org/10.1038/ sj.bjc.6605349.
34. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:5838-47; PMID:19884552; http://dx.doi.org/10.1200/JCO.2009. 22.1507.
35. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200.
36. Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 2011; 48:1512-7; PMID:21570725; http://dx.doi.org/10.1016/j.molimm.2011.04.010.
37. Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6; PMID:16330541; http://dx.doi.org/10.1074/jbc.M510171200.
38. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10. 1038/nri2206.
39. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057.
40. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103.
41. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754.
42. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10. 1200/JCO.2003.05.013.
43. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650-5; PMID:15355889; http://dx.doi.org/10.1158/1078-0432.CCR-04-0225.
44. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/ JCO.2007.14.8957.
45. Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 2007; 96:17-22; PMID:17391433; http://dx.doi.org/10.1111/j.1651-2227.2007.00199.x.
46. Ma S, Nashabeh W. Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Anal Chem 1999; 71:5185-92; PMID:10575965; http://dx.doi.org/10. 1021/ac990376z.
47. Lu Y, Wong WL, Meng YG. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods 2006; 314:74-9; PMID:16814318; http://dx.doi.org/10.1016/j.jim.2006.05. 011.
48. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200.
49. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-84; PMID:10754313.